Patents Examined by Hong Sang
  • Patent number: 11325951
    Abstract: This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: May 10, 2022
    Assignee: The General Hospital Corporation
    Inventors: Mark C. Poznansky, Jeffrey A. Gelfand
  • Patent number: 11318211
    Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: May 3, 2022
    Inventors: Jay Marshall Feingold, David Rodney Ungar
  • Patent number: 11312786
    Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: April 26, 2022
    Assignees: Aptevo Research and Development LLC, Alligator Bioscience AB
    Inventors: David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
  • Patent number: 11299543
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: April 12, 2022
    Assignees: Bristol-Myers Squibb Company, Seattle Genetics. Tnc.
    Inventors: Benedetto Farsaci, Neil Josephson, Anthony Cao, Ryan Heiser
  • Patent number: 11278628
    Abstract: This disclosure is directed to antibody-drug conjugates. More specifically, this disclosure is directed to compositions comprising (i) antibody-drug conjugates comprising benzodiazepines, and (ii) a small hydrophobic molecule, methods of treatment using the compositions, and methods of formulating the compositions. Furthermore, this disclosure is directed to methods of reducing reversible self-association in antibodies and in antibody-drug conjugates.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 22, 2022
    Assignee: IMMUNOGEN, INC.
    Inventor: Elizabeth Bartlett
  • Patent number: 11275087
    Abstract: The present invention relates to a test support method which is a means for predicting whether or not pathological complete response (pCR) will be attained when a preoperative chemotherapy with an anticancer drug is performed, the method using a sample (breast cancer tissue section) collected from a breast cancer patient to be subjected to the preoperative chemotherapy. The test support method includes: [1] the step of acquiring a fluorescence image of a breast cancer tissue section, which fluorescence image shows bright spots of fluorescent nanoparticles labeling one or more kinds of breast cancer-related proteins; [2] the step of acquiring at least one index relating to the expression level(s) of the breast cancer-related protein(s) on the basis of the bright spots of the fluorescence image; and [3] the step of acquiring information for predicting pCR by performing an analysis using the above-described at least one index.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: March 15, 2022
    Assignee: KONICA MINOLTA, INC.
    Inventors: Hideki Gouda, Masaru Takahashi, Kensaku Takanashi, Hisatake Okada, Yuichi Ozaki, Yuka Yoshihara, Yasushi Nakano, Kohsuke Gonda, Noriaki Ohuchi, Mika Watanabe, Norikazu Masuda, Masakazu Toi, Hiroshi Tada, Minoru Miyashita
  • Patent number: 11267900
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: March 8, 2022
    Assignees: Daiichi Sankyo Europe GmbH, Amgen Inc.
    Inventors: Mike Rothe, Martin Treder, Eric Borges, Larry L. Green, Susanne Hartmann
  • Patent number: 11246942
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 15, 2022
    Assignee: City of Hope
    Inventors: John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua Michael Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery, Jun Xie
  • Patent number: 11248047
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 15, 2022
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Patent number: 11242402
    Abstract: The present invention is directed to molecules, such as monospecific antibodies and bispecific, trispecific or multispecific binding molecules, including diabodies, BITE® molecules, and antibodies that are capable of specifically binding to “Disintegrin and Metalloproteinase Domain-containing Protein 9” (“ADAM9”). The invention particularly concerns such binding molecules that are capable of exhibiting high affinity binding to human and non-human ADAM9. The invention further particularly relates to such molecules that are thereby cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such ADAM9-binding molecules that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such ADAM9-binding molecule to a recipient subject.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 8, 2022
    Assignee: MacroGenics, Inc.
    Inventors: Deryk T. Loo, Juniper A. Scribner, Bhaswati Barat, Gundo Diedrich, Leslie S. Johnson, Ezio Bonvini
  • Patent number: 11236174
    Abstract: The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: February 1, 2022
    Inventors: Brian McGuinness, Isabelle Osuch, Chris Rossant, Mike Romanos, Nikki Royle, Thomas Sandal, Lorraine Thompson, Michele Writer
  • Patent number: 11219628
    Abstract: Provided herein are novel therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. For example, the compositions and methods herein lymphodeplete and reduce or ablate sites in the secondary lymphatics where the cellular immunotherapy is bound and sequestered, without the use of cytotoxic preconditioning.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: January 11, 2022
    Assignee: AVM Biotechnology, LLC
    Inventor: Theresa Deisher
  • Patent number: 11221334
    Abstract: The present invention provides a method for determining a treatment procedure for breast cancer, a method of predicting a likelihood of success in treating breast cancer, and a method for selecting an endocrine therapy agent for treating breast cancer. In particular, methods of the present invention rely on the amount of androgen receptor (AR) and estrogen receptor (ER) in a tissue sample.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: January 11, 2022
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Jennifer Richer Mouchantat
  • Patent number: 11213571
    Abstract: The present invention provides methods of modulating of cancer immunity using type 2 innate lymphoid cells (IL-C2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with therapies comprising type 2 innate lymphoid cells (ILC2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are diagnostic methods for assessing cancer prognosis.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 4, 2022
    Inventor: Wilfred Jefferies
  • Patent number: 11213583
    Abstract: The invention relates to compositions comprising a CD4 lymphocyte depleting agent; and methods of using the compositions to treat, prevent, reduce the severity of and/or slow the progression of a condition in a subject. The invention also relates to use of combinations of a CD4 lymphocyte depleting agent and at least one additional agent to treat, prevent, reduce the severity of and/or slow the progression of a condition in a subject. The additional agent may be an immune check point inhibitor, an adoptive immune therapeutic, an immune adjuvant, or an immune modulating agent, or their combinations.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 4, 2022
    Inventors: Hyung Kim, Yanping Wang
  • Patent number: 11208484
    Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: December 28, 2021
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xing Sun, Guoqing Cao, Changyong Yang, Lianshan Zhang, Yong Guo
  • Patent number: 11173180
    Abstract: The present application is directed to compositions and methods for treating a subject with cancer and/or increasing migration of a mesenchymal stromal cells (MSCs) stimulated with a recombinant autocrine motility factor (rAMF) to a tumor or a tumor cell, e.g. hepatocellular carcinoma (HCC). In addition, methods for increasing adhesion of MSCs to endothelial cells with rAMF are disclosed. In some embodiments, the MSCs comprise a therapeutic agent, e.g., an anti-tumor agent.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: November 16, 2021
    Assignee: Consejo National de Investigaciones Cientificas y Tecnicas (CONICET)
    Inventors: Guillermo Daniel Mazzolini, Mariana Gabriela Garcia, Juan Bayo
  • Patent number: 11167039
    Abstract: Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: November 9, 2021
    Assignee: Eli Lilly and Company
    Inventors: Yiqing Feng, Philip Arthur Hipskind, Renhua Li, Ling Liu, Takako Wilson, Aaron David Wrobleski
  • Patent number: 11155590
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: October 26, 2021
    Inventors: Colette Song, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 11155630
    Abstract: The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: October 26, 2021
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal